Cargando…
Statin tolerability: In defence of placebo-controlled trials
BACKGROUND: Statin intolerance is a barrier to effective lipid-lowering treatment. A significant number of patients stop prescribed statins, or can take only a reduced dose, because of adverse events attributed to the statin, and are then considered statin-intolerant. METHODS: Examination of differe...
Autores principales: | Tobert, Jonathan A, Newman, Connie B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847124/ https://www.ncbi.nlm.nih.gov/pubmed/26318980 http://dx.doi.org/10.1177/2047487315602861 |
Ejemplares similares
-
STATIN USE AT TIME OF RESPIRATORY VIRAL INFECTION IN PATIENTS WITH PRIOR HISTORY OF CARDIOVASCULAR DISEASE AND RISK OF SUBSEQUENT CARDIOVASCULAR EVENTS
por: Knight, Stacey, et al.
Publicado: (2015) -
The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case‐control study in a Korean nationwide cohort
por: Choi, Jin Ho, et al.
Publicado: (2019) -
An analysis of the effect of statins on the risk of Non‐Hodgkin's Lymphoma in the Women’s Health Initiative cohort
por: Desai, Pinkal, et al.
Publicado: (2018) -
Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis
por: Li, Yue, et al.
Publicado: (2019) -
Statin Use Reduces the Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis and Systematic Review
por: Khazaaleh, Shrouq, et al.
Publicado: (2022)